Page last updated: 2024-11-10

prostaglandin a1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5281912
CHEBI ID15545
SCHEMBL ID6417548
MeSH IDM0263940

Synonyms (60)

Synonym
BRD-K04010869-001-02-6
(13e,15s)-15-hydroxy-9-oxoprosta-10,13-dien-1-oic acid
CHEBI:15545 ,
prostaglandin a(sup 1)
pga(sup 1)
prostaglandin a(sub 1)
prostaglandin e(sup 1)-217
pga(sub 1)
BSPBIO_001458
LMFA03010005
9-oxo-15s-hydroxy-10z,13e-prostadienoic acid
15a-hydroxy-9-oxo-10,13e-prostadienoate
15a-hydroxy-9-oxo-10,13e-prostadienoic acid
IDI1_033928
7-[(1r,2s)-2-[(e,3s)-3-hydroxyoct-1-enyl]-5-oxo-cyclopent-3-en-1-yl]heptanoic acid
prosta-10,13-dien-1-oic acid, 15-hydroxy-9-oxo-, (13e,15s)-
prostaglandin a1
14152-28-4
pga1
prostaglandin a1, synthetic
NCGC00161282-01
NCGC00161282-02
NCGC00161282-03
HMS1989I20
BML1-F01
HMS1361I20
HMS1791I20
7-[(1r,2s)-2-[(e,3s)-3-hydroxyoct-1-enyl]-5-oxocyclopent-3-en-1-yl]heptanoic acid
vyr271n44p ,
unii-vyr271n44p
(13e,15s)-15-hydroxy-9-oxo-prosta-10,13-dien-1-oic acid
alprostadil impurity a [ep impurity]
prostaglandin a1 [usp-rs]
9-oxo-15s-hydroxy-prosta-10,13e-dien-1-oic acid
CCG-208253
BGKHCLZFGPIKKU-LDDQNKHRSA-N
SCHEMBL6417548
HMS3402I20
HMS3648A03
pga1 (prostaglandin a1)
prostaglandin a1, united states pharmacopeia (usp) reference standard
2-(3-hydroxy-1-octenyl)-5-oxo-3-cyclopentene-1-heptanoate
15-hydroxy-9-oxoprosta-10,13-dienoate
(13e,15s)-15-hydroxy-9-oxo-prosta-10,13-dien-1-oate
15a-hydroxy-9-ketoprosta-10,13-dienoate
2-(3-hydroxy-1-octenyl)-5-oxo-3-cyclopentene-1-heptanoic acid
15a-hydroxy-9-ketoprosta-10,13-dienoic acid
2-(3-hydroxy-1-octenyl)-5-oxo-3- cyclopentene-1-heptanoic acid
2-(3-hydroxy-1-octenyl)-5-oxo-3- cyclopentene-1-heptanoate
J-007508
eicosanoids_pga1_c20h32o4
pga1, prostaglandin a1, powder
prostaglandin a1 (pga1)
7-((1r,2s)-2-((s,e)-3-hydroxyoct-1-enyl)-5-oxocyclopent-3-enyl)heptanoic acid
Q27098093
15-hydroxy-9-oxoprosta-10,13-dienoic acid
SR-01000946186-1
sr-01000946186
pga1 (prostaglandin a1) is known as a cyclopentenone prostaglandin.
DTXSID601347314

Research Excerpts

Overview

Prostaglandin A1 is a powerful vasodepressor that augments renal blood flow and glomerular filtration. It possesses antiplatelet aggregator and oxytocic properties.

ExcerptReferenceRelevance
"Prostaglandin A1 is a powerful vasodepressor that augments renal blood flow and glomerular filtration and possesses antiplatelet aggregator and oxytocic properties."( Management of severe preeclampsia detected in early labor by prostaglandin A1 or dihydralazine infusions.
Barakat, AA; Darwish, E; Toppozada, MK, 1991
)
1.24

Effects

ExcerptReferenceRelevance
"Prostaglandin A1 has a profound inhibitory effect on uridine incorporation into RNA of normal cartilage whereas N6-monobutyryladenosine 3',5'-cyclic monophosphate is either stimulatory or without an effect. "( Hormonal and metabolic regulation of human chondrosarcoma in vitro.
Harrelson, JM; Lebovitz, HE; McCumbee, WD, 1983
)
1.71
"Prostaglandin A1 has a profound inhibitory effect on uridine incorporation into RNA of normal cartilage whereas N6-monobutyryladenosine 3',5'-cyclic monophosphate is either stimulatory or without an effect. "( Hormonal and metabolic regulation of human chondrosarcoma in vitro.
Harrelson, JM; Lebovitz, HE; McCumbee, WD, 1983
)
1.71

Dosage Studied

ExcerptRelevanceReference
" With this dosage a monophasic increase of portal blood flow and pressure was found with PGA1, PGE1, and PGE2, whereas PGF2 alpha caused a biphasic response: an initial decrease in portal blood flow and pressure was followed by an increase in these parameters."( Prostaglandins in diagnostic and therapeutic superior mesenteric artery pharmacoangiography.
Burgener, FA; Gutierrez, OH, 1986
)
0.27
" Lipid microspheres and Lipiodol formulation were examined as dosage form of the PGs and lipid microspheres were selected for further study."( Preparation and evaluation of o/w type emulsions containing antitumor prostaglandin.
Fukushima, M; Fukushima, S; Kishimoto, S; Takeuchi, Y, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
prostaglandins A
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency100.00000.354828.065989.1251AID504847
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency8.91250.00798.23321,122.0200AID2551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 2A1Rattus norvegicus (Norway rat)Ki0.28600.03821.41225.8000AID679001
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily A member 1Homo sapiens (human)EC50 (µMol)15.10000.00033.166210.0000AID482142
Nuclear receptor subfamily 4 group A member 2Homo sapiens (human)EC50 (µMol)5.00000.01002.89125.1000AID1885201; AID1885202
Nuclear receptor subfamily 4 group A member 2Mus musculus (house mouse)EC50 (µMol)5.00003.00004.00005.0000AID1885203; AID1885204
Nuclear receptor subfamily 4 group A member 2Rattus norvegicus (Norway rat)EC50 (µMol)5.00003.00004.00005.0000AID1885205; AID1885206
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
monoatomic ion transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to xenobiotic stimulusTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic cyclic compoundTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
response to hypoxiaNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron migrationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
response to amphetamineNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA-templated transcriptionNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
adult locomotory behaviorNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
post-embryonic developmentNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
central nervous system projection neuron axonogenesisNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
habenula developmentNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cellular response to oxidative stressNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of dopamine metabolic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
dopamine biosynthetic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron maturationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
negative regulation of neuron apoptotic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of respiratory gaseous exchangeNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
fat cell differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron apoptotic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
general adaptation syndromeNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
canonical Wnt signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
dopaminergic neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
midbrain dopaminergic neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
negative regulation of apoptotic signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
central nervous system neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature-gated cation channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
beta-catenin bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear retinoid X receptor bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein heterodimerization activityNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear glucocorticoid receptor bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
plasma membraneTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
stereocilium bundleTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
nucleusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nucleoplasmNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cytoplasmNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear speckNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein-containing complexNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nucleoplasmNuclear receptor subfamily 4 group A member 2Mus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID681874TP_TRANSPORTER: inhibition of alaninyl-d4TMP by Prostaglandin A1 at a concentration of 20uM in membrane vesicle from MRP5-expressing HEK293 cells2003Proceedings of the National Academy of Sciences of the United States of America, Aug-05, Volume: 100, Issue:16
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.
AID1885201Agonist activity at Nurr1 in human SK-N-BE(2)-C cells measured by NBRE-based luciferase reporter gene assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
AID1885204Agonist activity at Nurr1 in mouse MN9D cells measured by Gal4-based luciferase reporter gene assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
AID1885203Agonist activity at Nurr1 in mouse MN9D cells measured by NBRE-based luciferase reporter gene assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
AID1885202Agonist activity at Nurr1 in human SK-N-BE(2)-C cells measured by Gal4-based luciferase reporter gene assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
AID682102TP_TRANSPORTER: inhibition of alaninyl-d4TMP by Prostaglandin A1 at a concentration of 20uM in membrane vesicle from MRP3-expressing Sf9 cells2003Proceedings of the National Academy of Sciences of the United States of America, Aug-05, Volume: 100, Issue:16
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID681888TP_TRANSPORTER: inhibition of alaninyl-d4TMP in the presence of Prostaglandin A1 at a concentration of 20uM in membrane vesicles from MRP4-expressing Sf9 cells2003Proceedings of the National Academy of Sciences of the United States of America, Aug-05, Volume: 100, Issue:16
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.
AID679001TP_TRANSPORTER: inhibition of PGE2 uptake in PGT-expressing HeLa cells1996Molecular pharmacology, Oct, Volume: 50, Issue:4
Structural determinants of substrates for the prostaglandin transporter PGT.
AID482142Activation of TRPA1 channel2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
AID1885205Agonist activity at Nurr1 in rat N27-A cells measured by NBRE-based luciferase reporter gene assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1885206Agonist activity at Nurr1 in rat N27-A cells measured by Gal4-based luciferase reporter gene assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
AID681107TP_TRANSPORTER: inhibition of EA-GS uptake (EA-GS: 0.2 uM, GA1: 10 uM, in the presence of GSH) in membrane vesicles from MRP1-expressing DTY 168 yeast cells1997FEBS letters, Dec-08, Volume: 419, Issue:1
Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (202)

TimeframeStudies, This Drug (%)All Drugs %
pre-199068 (33.66)18.7374
1990's53 (26.24)18.2507
2000's58 (28.71)29.6817
2010's16 (7.92)24.3611
2020's7 (3.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.69 (24.57)
Research Supply Index5.34 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews7 (3.37%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other201 (96.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]